Align TechnologyXTER:AFW 89 Net Margin % is 10.84% as of Mar. 2026, which is 35% below its 10-year median of 16.64. GuruFocus rates XTER:AFW with a GF Score™ of 89/100 and a GF Value™ of €212.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Align Technology ranks better than 74.54% on this metric.
The historical rank and industry rank for Align Technology's Net Margin % or its related term are showing as below:
XTER:AFW'
s Net Margin % Range Over the Past 10 Years
Min: 9.68 Med: 16.64 Max: 71.84
Current: 10.5
XTER:AFW's Net Margin % is ranked better than 74.54% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs XTER:AFW: 10.50
Align Technology (XTER:AFW) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Align Technology Net Margin % Related Terms
Align Technology Net Margin % Historical Data
* Premium members only.
The historical data trend for Align Technology's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AFW vs SOLV, COO, BAX: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Align Technology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Align Technology Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Align Technology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Align Technology (XTER:AFW) has a Net Margin % of 10.84% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Align Technology and its competitors. This is 35% below median its historical median of 16.64. Over the past decade, Align Technology's Net Margin % has ranged from 9.68 to 71.84. According to the industry distribution chart, Align Technology ranks #208 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Align Technology's Net Margin % too high?
Align Technology's current Net Margin % of 10.84% is 35% below median its 10-year median of 16.64. Over the past 10 years, this metric has ranged from a low of 9.68 to a high of 71.84. The Medical Devices & Instruments industry median Net Margin % is 2.07. Align Technology's value of 10.84% is 423.7% above this industry median. Based on the distribution chart, Align Technology ranks #208 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Align Technology has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Align Technology's Net Margin % compare to SOLV and COO?
According to the Medical Devices & Instruments industry distribution chart, Align Technology ranks #208 out of 817 companies for Net Margin %. This puts Align Technology in the upper half of its industry. The industry median Net Margin % is 2.07. Align Technology's value of 10.84% is 423.7% above this benchmark. Historically, Align Technology's own Net Margin % has ranged from 9.68 to 71.84 over the past decade. While the company's 10-year median is 16.64 vs. the industry median of 2.07, Align Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Align Technology's current Net Margin % of 10.84% is 423.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Align Technology and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Align Technology's current Net Margin % is 10.84%, which is 35% below median its own 10-year median of 16.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Align Technology stock overvalued right now?
Based on GuruFocus' analysis, Align Technology (XTER:AFW) is currently considered Significantly Undervalued. The stock's GF Value™ is €212.06, compared to a current price of €149.05 — trading 29.7% below its estimated fair value. The current Net Margin % is 10.84%, which is 35% below median its 10-year median of 16.64 and 423.7% above the Medical Devices & Instruments industry median of 2.07. Align Technology's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Align Technology (XTER:AFW), the current Net Margin % is 10.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Align Technology (XTER:AFW) Overvalued in 2026?
Based on GuruFocus' analysis, Align Technology stock appears to be undervalued.
The current stock price of €149.05 is trading 29.7% below its estimated GF Value™ of €212.06.
GuruFocus considers Align Technology to be Significantly Undervalued.
Key valuation signals for XTER:AFW:
Net Margin %: 10.84% (35% below median its 10-year median of 16.64)
GF Value™: €212.06 vs. price of €149.05 (29.7% below fair value)
Industry Position: 423.7% above the Medical Devices & Instruments median (#208 of 817)
No single metric tells the full story. See the XTER:AFW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
89GF Score
Get the complete analysis for XTER:AFW
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AFW has been successfully added to your 
